Novavax, Inc. (NVAX) News
Filter NVAX News Items
NVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVAX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
Moderna stock forfeits gains as first US bird flu death puts vaccine development in focusThe first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. |
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowRecently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. |
Novavax (NASDAQ:NVAX) surges 35% this week, taking five-year gains to 171%Novavax, Inc. ( NASDAQ:NVAX ) shareholders might be concerned after seeing the share price drop 15% in the last... |
Vaccine Stocks Jump After CDC Reports First US Bird-Flu DeathThe first bird-flu fatality in the United States sparks investor interest in several vaccine makers that are developing experimental H5N1 vaccines. |
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid SpikeModerna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests. |
Vaccine Stocks Surge: Moderna Jumps 11% as COVID-19 and Flu Fears Reignite Immunization DemandModerna leads vaccine rally amid rising respiratory infections, spurring investment in COVID-19, flu, and RSV solutions. |
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on ItRecently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. |
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024?Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024? |
Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million MilestoneNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its partnership with Sanofi. The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. |